- Home
- FBIN vs RPRX Comparison
FBIN vs RPRX Comparison
Compare FBIN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIN
- RPRX
- Stock Information
- Founded
- FBIN 1988
- RPRX 1996
- Country
- FBIN United States
- RPRX United States
- Employees
- FBIN N/A
- RPRX N/A
- Industry
- FBIN Building Products
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FBIN Consumer Discretionary
- RPRX Health Care
- Exchange
- FBIN Nasdaq
- RPRX Nasdaq
- Market Cap
- FBIN 9.2B
- RPRX 11.8B
- IPO Year
- FBIN N/A
- RPRX 2020
- Fundamental
- Price
- FBIN $73.89
- RPRX $25.70
- Analyst Decision
- FBIN Buy
- RPRX Strong Buy
- Analyst Count
- FBIN 12
- RPRX 6
- Target Price
- FBIN $91.36
- RPRX $41.67
- AVG Volume (30 Days)
- FBIN 1.3M
- RPRX 2.5M
- Earning Date
- FBIN 11-06-2024
- RPRX 11-06-2024
- Dividend Yield
- FBIN 1.30%
- RPRX 3.27%
- EPS Growth
- FBIN 5.28
- RPRX 518.56
- EPS
- FBIN 3.55
- RPRX 2.55
- Revenue
- FBIN $4,666,100,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- FBIN $3.71
- RPRX $12.38
- Revenue Next Year
- FBIN $3.58
- RPRX $11.26
- P/E Ratio
- FBIN $20.85
- RPRX $10.06
- Revenue Growth
- FBIN 1.51
- RPRX N/A
- 52 Week Low
- FBIN $62.54
- RPRX $25.10
- 52 Week High
- FBIN $90.54
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- FBIN 24.17
- RPRX 30.45
- Support Level
- FBIN $75.11
- RPRX $26.08
- Resistance Level
- FBIN $86.96
- RPRX $28.36
- Average True Range (ATR)
- FBIN 2.37
- RPRX 0.60
- MACD
- FBIN -1.15
- RPRX -0.13
- Stochastic Oscillator
- FBIN 0.53
- RPRX 18.40
About FBIN Fortune Brands Innovations Inc.
Fortune Brands Innovations is a leading home and security products company that has three reportable segments. The company's $2.6 billion water segment, led by the Moen brand, sells faucets, showers, and other plumbing fixtures; the $1.3 billion outdoors segment primarily sells entry doors under the Therma-Tru brand name and Fiberon-branded patio decking; and the $723 million security segment sells locks and other security devices under the Master Lock, SentrySafe, Yale, and August brand names.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.